Yaneva D - Search Results

1

A ubiquitin switch controls autocatalytic inactivation of the DNA-protein crosslink repair protease SPRTN.

Zhao S, Kieser A, Li HY, Reinking HK, Weickert P, Euteneuer S, Yaneva D, Acampora AC, Götz MJ, Feederle R, Stingele J. Zhao S, et al. Among authors: yaneva d. Nucleic Acids Res. 2021 Jan 25;49(2):902-915. doi: 10.1093/nar/gkaa1224. Nucleic Acids Res. 2021. PMID: 33348378 Free PMC article.

2

The FANCJ helicase unfolds DNA-protein crosslinks to promote their repair.

Yaneva D, Sparks JL, Donsbach M, Zhao S, Weickert P, Bezalel-Buch R, Stingele J, Walter JC. Yaneva D, et al. Mol Cell. 2023 Jan 5;83(1):43-56.e10. doi: 10.1016/j.molcel.2022.12.005. Mol Cell. 2023. PMID: 36608669 Free PMC article.

3

SPRTN patient variants cause global-genome DNA-protein crosslink repair defects.

Weickert P, Li HY, Götz MJ, Dürauer S, Yaneva D, Zhao S, Cordes J, Acampora AC, Forne I, Imhof A, Stingele J. Weickert P, et al. Among authors: yaneva d. Nat Commun. 2023 Jan 21;14(1):352. doi: 10.1038/s41467-023-35988-1. Nat Commun. 2023. PMID: 36681662 Free PMC article.

4

A non-proteolytic release mechanism for HMCES-DNA-protein crosslinks.

Donsbach M, Dürauer S, Grünert F, Nguyen KT, Nigam R, Yaneva D, Weickert P, Bezalel-Buch R, Semlow DR, Stingele J. Donsbach M, et al. Among authors: yaneva d. EMBO J. 2023 Sep 18;42(18):e113360. doi: 10.15252/embj.2022113360. Epub 2023 Jul 31. EMBO J. 2023. PMID: 37519246 Free PMC article.

5

A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.

Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS; Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators. Binkley N, et al. J Bone Miner Res. 2012 Aug;27(8):1821-9. doi: 10.1002/jbmr.1602. J Bone Miner Res. 2012. PMID: 22437792 Free article. Clinical Trial.

6

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Smolen JS, et al. Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5. Lancet. 2008. PMID: 18358926 Clinical Trial.

7

Ligand-based design, synthesis and primary in vivo screening of pyrrole derivatives as potential tricyclic anti-inflammatory agents.

Bijev A, Yaneva D, Bocheva A, Stoev G. Bijev A, et al. Among authors: yaneva d. Arzneimittelforschung. 2006;56(11):753-9. doi: 10.1055/s-0031-1296786. Arzneimittelforschung. 2006. PMID: 17220053

8

Synthesis, acute toxicity, and analgesic activity of new derivatives of pyrrole.

Danchev N, Bijev A, Yaneva D, Vladimirova S, Nikolova I. Danchev N, et al. Among authors: yaneva d. Arch Pharm (Weinheim). 2006 Dec;339(12):670-4. doi: 10.1002/ardp.200600116. Arch Pharm (Weinheim). 2006. PMID: 17109462

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters